{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:04:23Z","timestamp":1766466263684,"version":"3.37.3"},"reference-count":0,"publisher":"Instituto Nacional de Salud (Peru)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Peru Med Exp Salud Publica"],"abstract":"<jats:p>El desarrollo y producci\u00f3n de vacunas seguras y eficaces contra la enfermedad por coronavirus 2019 (COVID- 19) ofrece la esperanza para el control de la pandemia actual. Los eventos adversos posteriores a la inmunizaci\u00f3n son respuestas indeseadas o acontecimientos involuntarios que siguen a la vacunaci\u00f3n, y que deben ser cuidadosamente vigilados, ya que todas las vacunas, incluyendo las desarrolladas contra el SARSCoV- 2, requieren cumplir con los criterios de seguridad para su administraci\u00f3n en humanos. Se recopil\u00f3 la informaci\u00f3n de la base de datos de PubMed\/Medline durante los meses de agosto de 2020 a noviembre de 2021. La mayor\u00eda de los eventos adversos identificados en los ensayos cl\u00ednicos fueron leves o moderados; sin embargo, se identificaron eventos tromb\u00f3ticos asociados a algunas vacunas basadas en vectores virales contra la COVID-19 en estudios de seguimiento, aunque se requiere la conclusi\u00f3n de los distintos estudios en curso y vigilancia poscomercializaci\u00f3n para determinar todos los posibles eventos adversos y de especial inter\u00e9s.<\/jats:p>","DOI":"10.17843\/rpmesp.2021.384.9308","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T17:40:11Z","timestamp":1642527611000},"page":"634-42","source":"Crossref","is-referenced-by-count":5,"title":["Seguridad de las vacunas contra la COVID-19"],"prefix":"10.17843","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-4142","authenticated-orcid":false,"given":"Nataniel Aldo","family":"Chaparro M\u00e9rida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-6265","authenticated-orcid":false,"given":"Dayany Moreno","family":"Samper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-4142","authenticated-orcid":false,"given":"Alex Omar","family":"Franco Lacato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7920","published-online":{"date-parts":[[2021,12,22]]},"container-title":["Revista Peruana de Medicina Experimental y Salud P\u00fablica"],"original-title":[],"link":[{"URL":"https:\/\/rpmesp.ins.gob.pe\/index.php\/rpmesp\/article\/viewFile\/9308\/4633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/rpmesp.ins.gob.pe\/index.php\/rpmesp\/article\/viewFile\/9308\/4633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T17:40:55Z","timestamp":1642527655000},"score":1,"resource":{"primary":{"URL":"https:\/\/rpmesp.ins.gob.pe\/index.php\/rpmesp\/article\/view\/9308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,13]]}},"URL":"https:\/\/doi.org\/10.17843\/rpmesp.2021.384.9308","relation":{},"ISSN":["1726-4642","1726-4634"],"issn-type":[{"type":"electronic","value":"1726-4642"},{"type":"print","value":"1726-4634"}],"subject":[],"published":{"date-parts":[[2021,12,22]]}}}